Concord Wealth Partners Regeneron Pharmaceuticals, Inc. Transaction History
Concord Wealth Partners
- $559 Million
- Q2 2024
A detailed history of Concord Wealth Partners transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Concord Wealth Partners holds 900 shares of REGN stock, worth $937,926. This represents 0.17% of its overall portfolio holdings.
Number of Shares
900
Previous 530
69.81%
Holding current value
$937,926
Previous $510,000
85.29%
% of portfolio
0.17%
Previous 0.09%
Shares
15 transactions
Others Institutions Holding REGN
# of Institutions
1,463Shares Held
84.5MCall Options Held
907KPut Options Held
1.3M-
Vanguard Group Inc Valley Forge, PA8.99MShares$9.37 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$8.8 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY8.28MShares$8.63 Billion0.77% of portfolio
-
State Street Corp Boston, MA4.84MShares$5.05 Billion0.23% of portfolio
-
Capital World Investors Los Angeles, CA4.64MShares$4.83 Billion0.82% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $112B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...